Research Article

Increased Prevalence of Mutant Allele \textit{Pfdhps} 437G and \textit{Pfdhfr} Triple Mutation in \textit{Plasmodium falciparum} Isolates from a Rural Area of Gabon, Three Years after the Change of Malaria Treatment Policy

Jacques-Mari Ndong Ngomo, Denise Patricia Mawili-Mboumba, Noé Patrick M’Bondoukwe, Rosalie Nikiéma Ndong Ella, and Marielle Karine Bouyou Akotet

Department of Parasitology-Mycology and Tropical Medicine, Faculty of Medicine, Université des Sciences de la Santé, BP 4009, Libreville, Gabon

Correspondence should be addressed to Denise Patricia Mawili-Mboumba; dpmawili@gmail.com

Received 23 October 2015; Revised 22 January 2016; Accepted 16 February 2016

Academic Editor: Donatella Taramelli

Copyright © 2016 Jacques-Mari Ndong Ngomo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In Gabon, sulfadoxine-pyrimethamine (SP) is recommended for intermittent preventive treatment during pregnancy (IPTp-SP) and for uncomplicated malaria treatment through ACTs drug. \textit{P. falciparum} strains resistant to SP are frequent in areas where this drug is highly used and is associated with the occurrence of mutations on \textit{Plasmodium falciparum} dihydrofolate reductase (\textit{Pfdhfr}) and dihydropteroate synthetase (\textit{Pfdhps}) genes. The aim of the study was to compare the proportion of mutations on \textit{Pfdhfr} and \textit{Pfdhps} genes in isolates collected at Oyem in northern Gabon, in 2005 at the time of IPTp-SP introduction and three years later. Point mutations were analyzed by nested PCR-RFLP method. Among 91 isolates, more than 90% carried \textit{Pfdhfr} 108N and \textit{Pfdhfr} 59R alleles. Frequencies of \textit{Pfdhfr} 51I (98%) and \textit{Pfdhps} 437G (67.7%) mutant alleles were high in 2008. Mutations at codons 164, 540, and 581 were not detected. The proportion of the triple \textit{Pfdhfr} mutation and quadruple mutation including A437G was high: 91.9% in 2008 and 64.8% in 2008, respectively. The present study highlights an elevated frequency of \textit{Pfdhfr} and \textit{Pfdhps} mutant alleles, although quintuple mutations were not found in north Gabon. These data suggest the need of a continuous monitoring of SP resistance in Gabon.

1. Introduction

In the early 1980s, sulfadoxine-pyrimethamine (SP) has been adopted for treatment of malaria cases when chloroquine treatment failed in many Sub-Saharan African countries [1]. However, soon after its introduction, resistance to SP has gradually emerged and spread widely from Asia to Africa [2, 3]. Nevertheless, SP is currently recommended by the World Health Organization (WHO) as intermittent preventive treatment for malaria in pregnant woman (IPTp) and children (IPTi) in malaria-endemic areas; it is also used as partner molecule of artemisinin derivatives [4, 5]. It is known that the presence of specific mutations on \textit{Plasmodium falciparum} dihydrofolate reductase (\textit{Pfdhfr}) and \textit{Plasmodium falciparum} dihydropteroate synthetase (\textit{Pfdhps}) genes encoding for proteins involved in the folate biosynthesis pathway of \textit{P. falciparum} is related to SP resistance [6–8]. Molecular studies document the prevalence of these mutations in parasite populations across the African continent [9]. The \textit{Pfdhfr} double mutations N51I-S108N and C59R-S108N confer intermediate levels of resistance while triple mutation N51I-C59R-S108N increases the parasite strains level of resistance in Africa [1]. The quadruple mutant N51I-C59R-S108N-I164R shows highest \textit{ex vivo} resistance to pyrimethamine so far [6]. Similarly, an amino acid change at codon 437 on \textit{Pfdhps} enzyme is due to the key mutation associated with
sulfadoxine resistance. Additional changes at positions 540, 581, and 613 appear to increase its level [10]. The presence of quintuple mutation, composed of the combination of the Pf\textit{dhfr} triple mutation (NSII-C59R-S108N) and the Pf\textit{dhps} double mutation (437–540 or 437–581), increases the risk of therapeutic failure to SP [11]. However, the complexities of the evolutionary pressures that lead to the evolution of drug resistance are not well understood. Microbial systems that allow heterologous expression of malarial proteins provide the way to investigate patterns of evolution that can inform on the more complex factors that influence the evolution of drug resistance in clinical settings [12]. Indeed, preventive therapy based on SP use protects against parasite infection but induces the genesis of gametocytes and can promote the spread of resistant parasites [13]. In Gabon, IPTp-SP for pregnant women and artesunate-SP for uncomplicated malaria treatment are recommended by Malaria National Control Programme (MNCP) for malaria prevention and treatment, respectively. Five years after its introduction, the coverage with IPTp-SP two doses reached 60% [14]. Moreover, SP is still widely sold in pharmacies and distributors in remote areas from the country, despite the introduction of artemisinin combinations therapy (ACTs) for uncomplicated malaria treatment. 

At the beginning of the year 2000 before IPT-p-SP implementation, previous studies describing the distribution of drug resistance molecular markers (\textit{dhfr} and \textit{dhps} genes) have been carried out in different areas of the country. In the southeast area, in the Haut-Ogooué Province, at Franceville, the proportion of isolates carrying a mutation at codon 108 was of 52%, while mutations at codons 51 and 59 as well as triple mutation were not frequent [15]. In contrast, at the same period and near Franceville, in Bakoumba, the triple mutant DHFR genotype was frequently detected (71.8%) whereas 64.3% combined at least three DHFR and one DHPS mutations [16].

In other regions, such as in the north of Gabon, at Oyem, similar investigations were not performed. In this area, regardless of the implementation of new strategies for malaria control, malaria prevalence remains high [17]. At the time of the study period, malaria prevalence tends to decrease; however, it was above 40% up to now. In this town surrounded by the forest and with a low level of urbanization, malaria transmission is perennial and children are frequently infected and constitute the main reservoir of parasites. Among many factors, the presence of resistant parasites could contribute to maintaining malaria burden in this region. Use of genetic information, for the early detection of resistance and monitoring of drug resistant malaria, is a helpful epidemiological tool. Indeed, molecular markers of resistance have emerged as epidemiologic tools to investigate antimalarial drug resistance even before becoming clinically evident. In this area, a previous study reported a high prevalence of \textit{pfcrt} and \textit{pfmdr1} drug resistance molecular markers associated with amodiaquine resistance, a partner molecule of artemisinin derivatives in ACTs [18]. This is the first study that reports baseline information on the characteristics and implications of antimalarial drug resistance, in the north of Gabon, with the aim to provide a data baseline on drug resistance. Thus, the prevalence of mutations on Pf\textit{dhfr} and Pf\textit{dhps} genes was compared in isolates collected in 2005 at the time of IPTp-SP introduction and three years later at Oyem in north of Gabon.

2. Methods

2.1. Study Site. Participants have been recruited through two different cross sectional studies carried out in 2005 and in 2008 at the regional hospital of Oyem (Centre Hospitalier Regional d'Oyem (CHRO)). The hospital of Oyem is the main hospital of the north of the country, a regional hospital. The majority of the population of the Oyem city which accounts for more than 35000 inhabitants and that of the surrounding villages receive healthcare in this hospital. CHRO is one of the five sentinel sites selected for malaria survey by the Malaria National Control Programme (MNCP). At Oyem, malaria prevalence remains above 40% among febrile children for a decade, and infection is predominantly caused by \textit{P. falciparum} [17].

2.2. Patients and Samples. Isolates were collected from febrile children aged less than 11 years [19]. Patients who had positive blood smears and \textit{P. falciparum} mono-infection were selected. The oral consent of the parents or legal guardians was also obtained. Blood was spotted on filter paper for further genetic analysis. Demographic data and medical history were reported.

2.3. Malaria Diagnosis. \textit{P. falciparum} infection diagnosis was done by microscopic examination according to Lambaréné’s method [20]. Smears were read using a light microscope with the 100x objective. Parasitaemia was expressed as a number of parasites per microliter of blood and parasite species was identified in the matched thin blood smears. Smears were considered as negative if the examination read under 100 of oil immersion fields did not reveal any parasites. Malaria case was defined as a patient with an axillary temperature >37.5°C and \textit{Plasmodium falciparum} infection without WHO criteria of severity.

2.4. Pf\textit{dhfr} and Pf\textit{dhps} Genes Typing. Parasite nucleic acids were extracted from filter paper using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions and subsequently stored at −20°C until use. Pf\textit{dhfr} codons 108, 51, 59, and 164 and Pf\textit{dhps} codons 437, 540, and 581 were analyzed using nested PCR-restriction fragment length polymorphism (PCR-RFLP) method. Mutations were detected by digesting PCR products with the restriction enzymes as described by Duraising et al. [21]. Amplicons and digested products were subjected to electrophoresis on 1.5 and 3.0% agarose gels, respectively, and visualized under UV transillumination light after staining. Digested products were compared with reference and local \textit{P. falciparum} strains, which are 3D7: 51A-59C-108S-164I; PA2: 51A-59C-108A; C5: 51I-59R-108N-437A; and C4: 51N-59C-108N-437G; and for mutation at codons 540 and 581 local \textit{P. falciparum} isolates. Samples containing both wild type and mutant alleles were classified as mixed infections.
Table 1: Prevalence of mutations conferring resistance to sulfadoxine/pyrimethamine in *Plasmodium falciparum* isolates from Gabon.

| Gene | Genotypes | 2005 | 2008 | P |
|------|------------|------|------|---|
|      | n          | %    | n    |    |
| 108N | 29/29      | 100  | 60/62| 96.7 NS |
| 59R  | 27/29      | 93.1 | 61/62| 98.4 NS |
| 51I  | 14/29      | 48.3 | 59/62| 95.2 <0.01 |

**Pf\dhfr**

- Double mutation: 51I-59R
  - 2005: 21/29 (72.4%)
  - 2008: 62/62 (100%)
  - P < 0.01
- Double mutation: 51I-108N
  - 2005: 21/29 (72.4%)
  - 2008: 60/62 (97.7%)
  - P < 0.01
- Double mutation: 59R-108N
  - 2005: 29/29 (100%)
  - 2008: 60/62 (96.7%)
  - P < 0.01
- Triple mutation: 51I-59R-108N
  - 2005: 21/29 (72.4%)
  - 2008: 57/62 (91.9%)
  - 0.03

**Pf\dhps**

|        | 2005 | 2008 |    |
|--------|------|------|---|
|        | n    | %    |    |
| 437G   | 11/29| 37.9 | 42/62| 67.7 <0.01 |

Table 2: Prevalence of Pf\dhfr/Pf\dhps haplotypes.

| Haplotypes: Pf\dhfr/Pf\dhps | 2005 | 2008 | P |
|-----------------------------|------|------|---|
|                             | n    | %    | n  | %   |    |
| 108N-59C/R-51I-437G (NC/RIG) | 0/29 | 0    | 2/55| 3.6 NS |
| 108N-59R-51I-437A/G* (NRIA/G) | 1/29 | 3.4  | 0/55| 0 NS |
| 108N-59R-51I-437 (NRIA)     | 15/29| 51.7 | 16/55| 29.9 0.04 |
| 108S-59R-51I-437G (SRIG)    | 0/29 | 0    | 1/55| 1.8 NS |
| Quadruple mutation: 108N-59R-51I-437G | 10/29| 34.4 | 35/55| 64.8 0.01 |

* Parasites carrying mixed infections designated by two genotypes at the codon indicated above. NS: not significant. For the calculation of the haplotype frequencies, samples with both \dhfr and \dhps genes analysis have been selected.

2.5. Ethical Considerations. Department of Parasitology and Mycology (DPM) is committed by the Gabonese Ministry of Health represented by MNCP to carry out malaria diagnosis and antimalarial drug resistance monitoring throughout the country. Parents and legal guardians were informed about the studies and the consecutive molecular analysis. Their oral consent was obtained prior to inclusion in the study and before sample collection. Each patient with malaria positive blood smears was treated according to national recommendations at the time of the study.

2.6. Data Analysis. All data were entered and cleaned using Epi-info version 3.3.2. Analysis was performed with the Statview 5.0 software. All variables were compared using \( \chi^2 \) test or Fisher's exact test. \( p \) value < 0.05 was considered statistically significant.

3. Results

3.1. Characteristics of Patients. Ninety-one *P. falciparum* isolates available, 29 from 2005 and 62 from 2008, were analyzed. Children median age was of 33 [31–37] months and their median parasite density of 53514 [31251–75776] p/µL. Globally, 58% (n = 17) of the patients were male in 2005, while in 2008 the proportion of females (50%; n = 31) and males (50%; n = 31) was similar.

3.2. Prevalence of Pf\dhfr and Pf\dhps Mutations. Pf\dhfr mutant alleles, N108 and R59, were found in 97.8% and 96.7% of the isolates, respectively. The frequency of 151 mutant allele was lower (80.2%, n = 73) although not statistically different (\( p > 0.05 \)). No mutation was found at codons 540 and 581 of \dhps gene, but 58% of the isolates carried the mutant allele at codon 437. Between 2005 and 2008, the proportions of mutant alleles N108 and R59 were comparable (Table 1). In contrast, the frequency of mutation at codon 51 was almost twofold higher in isolates from 2008: 95.2% versus 48.3% in 2005 (\( p < 0.01 \)). The frequency of the double mutation 59-108 did not vary during the study period while the triple \dhfr mutation rate increased in 2008 reaching 91.9% (n = 57). As found for the \dhfr 151 mutant allele, the proportion of isolates carrying the mutant allele 437G was almost twofold higher in 2008: 67.7% (n = 42) versus 37.9% (n = 11) in 2005 (\( p < 0.01 \)) (Table 2). All parasites harbored a wild type allele at codons 164, 540, and 581 whatever the study period 2005 or 2008.

3.3. Haplotypes Pf\dhfr/Pf\dhps. For the calculation of the haplotype frequencies, samples with both \dhfr and \dhps genes analysis have been included. The frequency of haplotype combining the triple Pf\dhfr mutation and the wild type allele at codon 437 on \dhps gene [108N-59R-51I-A437 (NRIA)] decreased in 2008: 29.9% versus 51.7% in 2005 (0.04). Inversely, parasites carrying the quadruple mutation (triple \dhfr-437\dhps mutation) were 1.9-fold more frequent in 2008 (Table 2). No quintuple (\dhfr 51I/59R/108N and \dhps 437G/540E) mutation was found.

4. Discussion

Occurrence and expansion of *P. falciparum* mutant genotypes frequency may depend on various factors such as year and location of study and age and clinical status of sampled population. In the present study, the prevalence of mutations
on *Pfdhfr* and *Pfdhps* genes was compared in isolates collected in 2005 at the time of IPTp-SP introduction and three years later at Oyem, in the north of Gabon. Malaria prevalence there is above 40% and the treatment failures rates after SP administration were of 11.6% among children aged less than 5 years in 2005 [19]. In this area, the proportion of mutant alleles N108 and R59 of *Pfdhfr* gene in *P. falciparum* isolates was already high in 2005 and did not vary in 2008. Frequencies of these mutants’ alleles were comparable to those found in isolates collected during the same period, between 2005 and 2006, at Lambaréné in the centre of Gabon and Libreville, the capital city of Gabon, two areas where malaria prevalence is different [22, 23]. Likewise, during the year 2006, in Kenya, more than 95% of *P. falciparum* isolates carried *dhfr* mutant alleles, a proportion that was already around 80% in the 1990s [24]. In contrast, in Iran and Senegal where malaria transmission is lower, during the same period, such high prevalence of *dhfr* mutant alleles was not found (<90%) [25, 26]. Concerning the mutant allele 51I, its frequency was above 75% in Lambaréné (79%) and Libreville (92%) while at Oyem it did not reach 50% (48.3%) [22, 23]. However, very quickly, in 2008, this allele was found in more than 95% of *P. falciparum* isolates collected at Oyem, a proportion comparable to those reported in regions from Congo (88%) and Benin (>90%) [27, 28]. Mutation at codon 164, which is associated with an elevated level of pyrimethamine resistance, was not detected. This mutation is rare in Africa [28, 29]. The triple *dhfr* mutation was also frequently detected at Oyem in 2008 (>90%), in a proportion comparable to the one found in Senegal (93%) and Benin (91.8%) in 2011 but higher compared to the ones found in Burkina Faso (54.3%) and Rwanda (78%) during the same period [26, 30]. In Iran, where malaria transmission is low and although sulfadoxine/pyrimethamine-artesunate combination has been adopted and recommended as first-line drug treatment the proportion of the triple mutation 108N-59R-437G is constant around 39% [25]. The combination of the triple mutation *Pfdhfr* and 437G mutation of the gene *Pfdhps* was found in two-thirds of the isolates analyzed in the present study, while in Senegal 44% of the isolates carried this haplotype [26].

The data obtained during the present study and those from previous investigations underline a different distribution and evolution of SP molecular markers resistance in Gabon. Indeed, while proportions of triple *dhfr* mutation and 151 mutant allele were already high in Lambaréné and Libreville during the years 2005-2006, at Oyem comparable frequencies were reached three years after in 2008. Nevertheless, between 2005 and 2011 at Libreville, the triple *Pfdhfr* mutation frequency increased from 92.9% to 100% and multiple mutation from 17.9% to 75.6% [31]. *Dhps* mutant alleles at codons 581 and 540 as well as the *dhfr-dhps* quintuple mutation were not found at Oyem while they were detected at Libreville and Lambaréné. The presence of the *dhfr-dhps* quintuple mutation in *P. falciparum* isolates is reported to be a good indicator of the abandonment of the SP [9, 23, 32, 33]. These mutations were detected in 4% and 22% of the isolates from Lambaréné and Libreville, respectively. The main limitation of the present study could be the small number of isolates available and analyzed. However, these data provide important information allowing the setup of a database on antimalarial drug resistance molecular markers in Gabon. Indeed, although the number of samples is small, it is possible to draw from the present analyses accurate data and information on the prevalence of mutant parasites circulating in this area as performed by others [34]. These data already represent an “alarm” in this area where malaria transmission is high and suggest at least an increasing drug pressure in this area, related presumably to SP or other antifolates use.

5. Conclusion

The present study shows that *Pfdhfr* and *Pfdhps* mutant allele’s frequencies are elevated, probably due to an increased use of sulfadoxine-pyrimethamine at Oyem. Three years after the adoption of WHO recommendation, frequencies of the combination of triple *Pfdhfr* mutation and *Pfdhps* 437G allele have risen, although among multiple mutations detected the quintuple mutation was not found. The monitoring of drug resistance molecular markers should be performed regularly and associated with the assessment of SP efficacy *in vivo* or *ex vivo* assays for Oyem.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

The present study was initiated by Denise Patricia Mawili-Mboumba and Marielle Karine Bouyou Akotet; genotyping of isolates was done by Jacques-Mari Ndong Ngomo, Noé Patrick M’Bondoukwe, and Rosalie Nikiema Ndong Ella.

Data processing was performed by Marielle Karine Bouyou Akotet. The paper was written by Jacques-Mari Ndong Ngomo, Denise Patricia Mawili-Mboumba, and Marielle Karine Bouyou Akotet. The paper was accepted and approved by all the authors.

Acknowledgments

The authors are grateful to parents or guardians of children who have participated in both studies and to CHRO staff for its collaboration with the Parasitology-Mycology Department of the Faculty of Medicine Libreville.

References

[1] C. Roper, R. Pearce, B. Bredenkamp et al., “Antifolate antimalarial resistance in southeast Africa: a population-based analysis,” *The Lancet*, vol. 361, no. 9364, pp. 1174–1181, 2003.

[2] C. Roper, R. Pearce, S. Nair, B. Sharp, F. Nosten, and T. Anderson, “Intercontinental spread of pyrimethamine-resistant malaria,” *Science*, vol. 305, no. 5687, p. 1124, 2004.

[3] Wongsrichanalai, A. L. Pickard, W. H. Wernsdorfer, and S. R. Meshnick, “Epidemiology of drug-resistant malaria,” *The Lancet Infectious Diseases*, vol. 2, no. 4, pp. 209–218, 2002.
[4] World Malaria Report 2011, http://www.who.int/malaria/world_malaria_report_2011/en/index.html.

[5] WHO: World Health Organization, A Strategic Framework for Malaria Prevention and Control during Pregnancy in the African Region, AFR/MAL/04/01, WHO Regional Office for Africa, Brazzaville, Congo, 2004.

[6] D. Bzik, W.-B. Li, T. Horii, and J. Inselsburg, "Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene," Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 23, pp. 8360–8364, 1987.

[7] D. R. Brooks, P. Wang, M. Read, W. M. Watkins, P. F. Sims, and J. E. Hyde, "Sequence variation of the hydroxymethylidydropterin pyrophosphokinase: dihydropterate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine," European Journal of Biochemistry, vol. 224, no. 2, pp. 397–405, 1994.

[8] A. E. Cowman, M. J. Morry, B. A. Biggs, G. A. M. Cross, and S. J. Foote, "Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum," Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 23, pp. 9109–9113, 1988.

[9] S. Sriran, S. K. McIntock, L. M. Syphard, K. M. Herman, J. W. Barnwell, and V. Udhayakumar, "Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations," Malaria Journal, vol. 9, no. 1, article 247, 2010.

[10] W. H. Werndsoer and H. Noedl, "Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology," Current Opinion in Infectious Diseases, vol. 16, no. 6, pp. 553–558, 2003.

[11] S. Picot, P. Olliario, F. De Monbrison, A.-L. Bienvenu, R. N. Price, and P. Ringwald, "A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria," Malaria Journal, vol. 8, article 89, 2009.

[12] M. S. Costanzo and D. L. Hartl, "The evolutionary landscape of antifolate resistance in Plasmodium falciparum," Journal of Genetics, vol. 90, no. 2, pp. 187–190, 2011.

[13] J. T. Boussana, L. C. Gouagna, A. M. Meutsteg et al., "Treatment failure of pyrimethamine-sulfadoxine and induction of Plasmodium falciparum gametocytamia in children in western Kenya," Tropical Medicine and International Health, vol. 8, no. 5, pp. 427–430, 2003.

[14] M. K. Bouyou-Aketot, D. P. Mawili-Mboumba, and M. Kombila, "Antenatal care visit attendance, intermittent preventive treatment and bed net use during pregnancy in Gabon," BMC Pregnancy and Childbirth, vol. 13, article 52, 2013.

[15] D.-P. Mawili-Mboumba, M.-T. Ekala, F. Lekoulou, and F. Ntoumi, "Molecular analysis of DHFR and DHPS genes in P. falciparum clinical isolates from the Haut-Ogooué region in Gabon," Acta Tropica, vol. 78, no. 3, pp. 231–240, 2001.

[16] A. Aubouy, S. Jafari, V. Huard et al., "DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethane and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy," Journal of Antimicrobial Chemotherapy, vol. 52, no. 1, pp. 43–49, 2003.

[17] D. P. Mawili-Mboumba, M. K. B. Akotet, E. Kendjo et al., "Increase in malaria prevalence and age of at risk population in different areas of Gabon," Malaria Journal, vol. 12, no. 1, article 3, 2013.

[18] D. P. Mawili-Mboumba, J. M. N. Ngomo, F. Maboko et al., "Pcrf 76T and pfmdrl 86Y allele frequency in plasmodium falciparum isolates and use of self-medication in a rural area of Gabon," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 108, no. 11, Article ID tru47, pp. 729–734, 2014.

[19] B. Nsamba, V. Guiyedi, M. Mabika-Mamfoumbi et al., "Sulfadoxine-pyrimethamine versus amodiquine for treating uncomplicated childhood malaria in Gabon: a randomized trial to guide the national policy," Malaria Journal, vol. 7, article 31, 2008.

[20] T. Planche, S. Krishna, M. Kombila et al., "Comparison of methods for the rapid laboratory assessment of children with malaria," The American Journal of Tropical Medicine and Hygiene, vol. 65, no. 5, pp. 599–602, 2001.

[21] M. T. Duraisingham, J. Curtis, and D. C. Warhurst, "Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropterate synthetase genes by PCR and restriction digestion," Experimental Parasitology, vol. 89, no. 1, pp. 1–8, 1998.

[22] G. Mombo-Ngoma, S. Oyakirome, R. Ord et al., "High prevalence of dhfr triple mutant and correlation with high rates of sulfadoxine-pyrimethamine treatment failures in vivo in Gabonese children," Malaria Journal, vol. 10, article 123, 2011.

[23] M. K. Bouyou-Aketot, D. P. Mawili-Mboumba, T. de Dieu Tchantchou, and M. Kombila, "High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon," Journal of Antimicrobial Chemotherapy, vol. 65, no. 3, pp. 438–441, 2010.

[24] L. Mwai, E. Ochong, A. Abdirahman et al., "Chloroquine resistance before and after its withdrawal in Kenya," Malaria Journal, vol. 8, article 106, 2009.

[25] M. Afsharpad, S. Zakeri, S. Pirahmadi, and N. D. Djadid, "Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine-pyrimethamine plus artesunate as the first line treatment in Iran," Acta Tropica, vol. 121, no. 1, pp. 13–18, 2012.

[26] D. Ndiaye, B. Dieye, Y. D. Ndiaye et al., "Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in thies, senegal," International Journal for Parasitology: Drugs and Drug Resistance, vol. 3, pp. 135–142, 2013.

[27] F. Koukouikila-Koussounda, D. Bakoua, A. Fesser, M. Nkombo, C. Vouvoungui, and F. Ntoumi, "High prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo," Infection, Genetics and Evolution, vol. 33, pp. 32–36, 2015.

[28] A. Ogouyémi-Hounto, N. T. Ndam, D. K. Gazard et al., "Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulfadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy," Malaria Journal, vol. 12, article 147, 2013.

[29] J. P. Wendler, J. Okombo, R. Amato et al., "A genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in Kenya," PLoS ONE, vol. 9, no. 5, Article ID e96486, 2014.

[30] C. Geiger, G. Compafro, B. Coulibly et al., "Substantial increase in mutations in the genes pfidfr and pfidhs
puts sulphadoxine-pyrimethamine-based intermittent preventive treatment for malaria at risk in Burkina Faso," *Tropical Medicine and International Health*, vol. 19, no. 6, pp. 690–697, 2014.

[31] M. K. Bouyou-Akotet, M.-L. Tshibola, D. P. Mawili-Mboumba et al., "Frequencies of dhfr/dhps multiple mutations and *Plasmodium falciparum* submicroscopic gametocyte carriage in Gabonese pregnant women following IPTp-SP implementation," *Acta Parasitologica*, vol. 60, no. 2, pp. 218–225, 2015.

[32] A. M. Nzila, E. K. Mberu, J. Sulo et al., "Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites," *Antimicrobial Agents and Chemotherapy*, vol. 44, no. 4, pp. 991–996, 2000.

[33] J. G. Kublin, F. K. Dzinjalamala, D. D. Kamwendo et al., "Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria," *Journal of Infectious Diseases*, vol. 185, no. 3, pp. 380–388, 2002.

[34] R. A. Mubjer, A. A. Adeel, M. L. Chance, and A. A. Hassan, "Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications," *Malaria Journal*, vol. 10, article 245, 2011.